Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
MWN-AI** Summary
Emergent BioSolutions has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approval of its supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray multipacks. Announced on February 12, 2026, this approval introduces 6-count and 24-count multipack configurations of the naloxone nasal spray, which is critical for emergency treatment of opioid overdoses. The new packaging options are tailored to enhance flexibility for partners involved in distributing larger quantities of this life-saving medication.
Paul Williams, senior vice president at Emergent, highlighted that the multipacks represent a crucial development for their collaborators working on the front lines. By streamlining bulk distribution, these new configurations will support broader preparedness initiatives, ensuring that more communities have timely access to NARCAN® during overdose emergencies.
This approval complements Emergent's ongoing efforts to improve the accessibility and usability of NARCAN®, following the FDA's recent endorsement of a carrying case for the product in January 2026. Such initiatives demonstrate the company’s dedication to empowering organizations and individuals in combating opioid overdoses, a pressing public health issue.
NARCAN® Nasal Spray is notable as the first FDA-approved, over-the-counter naloxone product for emergency opioid overdose intervention. Despite the introduction of multipacks, Emergent will maintain its existing product formats, which have already facilitated the distribution of over 85 million doses since the product's prescription launch in 2016.
The multipacks will soon be available via NARCANDirect®, Emergent's ordering and distribution platform, marking another step forward in the company’s mission to protect lives against health threats. This initiative reiterates Emergent BioSolutions' commitment to public health and readiness to address the opioid crisis effectively.
MWN-AI** Analysis
Emergent BioSolutions (NYSE: EBS) recently received U.S. FDA approval for the supplemental New Drug Application (sNDA) for new multipack configurations of its NARCAN® Nasal Spray, a significant development that warrants close attention from investors. The expanded product suite, which includes 6-count and 24-count multipack options, enhances the accessibility and distribution efficiency of this life-saving opioid overdose treatment, thereby broadening Emergent's market potential.
From a market perspective, this approval can strengthen Emergent's position in the burgeoning naloxone market, which has seen increasing demand due to the ongoing opioid crisis. By introducing multipacks, Emergent addresses the needs of large-scale community distribution programs, effectively positioning itself to meet the demands of state and local governments, healthcare organizations, and non-profit entities focused on combating opioid overdoses. This strategic move not only demonstrates Emergent's adaptability but also underscores its commitment to public health.
Investors should note that the multipacks are expected to be available soon via NARCANDirect®, Emergent's proprietary ordering platform, enhancing convenience and potentially driving sales growth. Additionally, this launch comes on the heels of approvals for complementary products, indicating a robust pipeline that could support sustained revenue generation.
However, it’s crucial to evaluate potential risks. Market competition in the healthcare sector, regulatory changes, or shifts in public funding for naloxone programs may impact sales. Investors should stay informed of these factors and consider the company's comprehensive strategy to mitigate risks associated with opioid overdose treatment accessibility.
Overall, given the increasing recognition of the opioid epidemic and the urgency for accessible treatment options, Emergent BioSolutions stands to benefit significantly from this approval. Stakeholders may find current levels attractive for entry, betting on future growth bolstered by strategic product offerings designed to meet real-world needs.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication
GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. This approval expands the NARCAN® Nasal Spray product suite to include 6-count and 24-count multipack options, specifically designed to meet the needs of partners distributing higher volumes of naloxone. These new formats offer enhanced flexibility with the same trusted product, benefiting community programs and organizations operating large-scale, multi-site, or high-volume distribution programs.
“At Emergent, we work closely with our partners to develop solutions that help improve delivery, distribution and accessibility of NARCAN® Nasal Spray,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “The introduction of NARCAN® Nasal Spray multipacks marks a significant step in empowering our partners on the front lines. They can now better streamline bulk distribution, support broad preparedness efforts, and ultimately ensure that more communities and individuals have ready access to this life-saving medication in the event of an opioid overdose emergency.”
This approval builds on Emergent's ongoing commitment to enhancing NARCAN® Nasal Spray accessibility and usability, complementing the recent FDA approval of the NARCAN® Nasal Spray Carrying Case in January 2026. These efforts underscore Emergent’s comprehensive approach to equipping individuals and organizations with effective tools to combat opioid overdose deaths. The 6-count and 24-count multipacks will be made available soon to purchase for public interest customers through NARCANDirect®, Emergent’s proprietary ordering and distribution platform. These multipacks are an addition to the current portfolio and will not replace existing product formats. Since the prescription launch of NARCAN® Nasal Spray in 2016, more than 85 million doses have been distributed across the U.S. and Canada. Visit NARCAN.com and ReadytoRescue.com to learn more.
About NARCAN® Nasal Spray
NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years,?we’ve?been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola,?anthrax?and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our?website?and follow us on?LinkedIn,?X,?Instagram,?Apple Podcasts?and?Spotify.?
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company's actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ**
How will the new multipack configurations of NARCAN® Nasal Spray improve distribution efficiency for Emergent Biosolutions Inc. EBS and its partners in combatting opioid overdose emergencies?
Can Emergent Biosolutions Inc. EBS provide insights into how the 6-count and 24-count multipacks will impact pricing strategies and overall cost-effectiveness for community programs?
What specific feedback from partners influenced the decision by Emergent Biosolutions Inc. EBS to expand the NARCAN® Nasal Spray portfolio with these new multipack options?
How does Emergent Biosolutions Inc. EBS plan to ensure the accessibility of the new multipack configurations of NARCAN® to communities most affected by opioid overdoses?
**MWN-AI FAQ is based on asking OpenAI questions about Emergent Biosolutions Inc. (NYSE: EBS).
NASDAQ: EBS
EBS Trading
-0.06% G/L:
$8.065 Last:
212,002 Volume:
$8.23 Open:
